Cadila Healthcare reported 41-percent rise in its consolidated net profit to Rs 527.2 crore for the quarter ended December’20 on account of robust sales in all segments.
Consolidated revenue of the company stood at Rs 3,795.6 crore. Whereas it was Rs 3,638.1 crore for the same period a year ago, as said by Cadila Healthcare filing to BSE.
Continuing its fight against COVID-19, the company received approvals to start phase-III clinical-trials of Pegylated Interferon Alpha-2b. It also got the approval to start phase-III clinical-trials of its vaccine ZyCoV-D. The trials for the vaccine are underway and will test 30,000 healthy adult volunteers across 60 locations.
Cadila also launched the oral anti-diabetic agent, Dapaglyn for patients suffering from Chronic Obstructive Pulmonary Disorder.
Shares of Cadila-listed entity of Zydus Group, were trading at Rs 481.30 per-scrip on BSE, up 0.45 percent from previous close.
